APAC Intragastric Balloon Market Industry Trends and Forecast to 2034: Segmented by (Type, Filling, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$57.5 MnPlaceholder estimate
Estimate 2025$64.7 Mn21% of the global market
Projected 2034$186.7 Mn 188.7%Adds $122.0 Mn over 9 forecast years
CAGR 2025–203412.5%Faster than 67% of 173 Medical Devices markets here
Key players5Companies profiled
APAC is 21% of the global market.
Among regions, the largest is North America at $145.1 Mn.
Allurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics, Helioscopie (see all)
Active clinical trials
2 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Intragastric Balloon Market Analysis Executive Summary
Intragastric balloons are soft balloons placed in the stomach for a few months to help people eat less and lose weight without surgery.
Key segments of the intragastric Balloon market include type (Single Balloon, Dual Balloon and Swallowable Balloon) and filling (Saline-Filled and Gas-Filled).
Asia Pacific Intragastric Balloon market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Intragastric Balloon Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the intragastric Balloon market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the intragastric Balloon market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Intragastric Balloon Market in APAC
The intragastric Balloon market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Intragastric Balloon Market in APAC
Intragastric Balloon in APAC: rules, payment and research
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 2 studies on Intragastric Balloon that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how intragastric Balloon products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Filling
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Allurion Technologies
7.2 Apollo Endosurgery
7.3 Spatz Medical
7.4 Obalon Therapeutics
7.5 Helioscopie
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The intragastric Balloon market can be segmented based on various criteria, including type, filling and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Intragastric Balloon right now, from free public sources.
Clinical trials
2 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Intragastric Balloon market in Asia Pacific?
Placeholder estimate: about $64.7 Mn in 2025, rising to about $186.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Intragastric Balloon market in Asia Pacific growing?
Placeholder estimate: about 12.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Intragastric Balloon market report cover?
The report splits the market by type (Single Balloon, Dual Balloon, Swallowable Balloon), filling (Saline-Filled, Gas-Filled) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Intragastric Balloon market?
Key players include Allurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics and Helioscopie.
What is driving the Intragastric Balloon market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market.
How many clinical trials on Intragastric Balloon are running in Asia Pacific?
2 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Intragastric Balloon?
PubMed lists 302 papers on Intragastric Balloon added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.